



The Drug Utilization Review (DUR) Board Reviewed
the Following New Drugs/Classes on
August 2, 2022

Therapeutic Class	Drug Name	DURB Recommendation
HIV/AIDS		
	<i>Apretude (Intramuscular) Injection</i>	P (for coverage on the PADL)
Lipotropics, Other		
	<i>Leqvio (Subcutaneous) Injection</i>	NP/PA (for coverage on the PADL)
Antimigraine Agents, Other		
	<i>Qulipta (Oral) Tablet</i>	P/PA
Immunomodulators, Asthma		
	<i>Tezspire (Subcutaneous) Injection</i>	NP/PA (for coverage on the PADL)
Macular Degeneration Agents		
	<i>Vabysmo (Intravitreal) Injection</i>	P/PA (for coverage on the PADL)
Ophthalmics, Anti-Inflammatories		
	<i>Xipere (Suprachoroidal) Injection</i>	P/PA (for coverage on the PADL)

DURB=Drug Utilization Review Board; P=preferred; NP=non-preferred; PA=prior authorization; PDL=Preferred Drug List; PADL=Providers' Administered Drug List